Today's guest post comes from Bryce Aronson, Director of Business Development at AssistRx. Bryce covers three considerations taking effect in January 2027—the end of Medicare Part D premium support, a faster Medicaid redetermination timeline, and the shift away from once-a-year reverification—and what they mean for patient support programs. He explores how affordability solutions can help reduce coverage disruptions, minimize unnecessary PAP utilization, and maintain continuity of therapy throughout the transition. To learn more about AssistRx's affordability solutions, access their webinar, State of Patient Support 2026: Turning Regulatory Policy, AI and Direct-to-Patient Pressure into Program Strategy . Read on for Bryce's…
Today's guest post comes from Bryce Aronson, Director of Business Development at AssistRx.
Bryce covers three considerations taking effect in January 2027—the end of Medicare Part D premium support, a faster Medicaid redetermination timeline, and the shift away from once-a-year reverification—and what they mean for patient support programs. He explores how affordability solutions can help reduce coverage disruptions, minimize unnecessary PAP utilization, and maintain continuity of therapy throughout the transition.
To learn more about AssistRx's affordability solutions, access their webinar,
State of Patient Support 2026: Turning Regulatory Policy, AI and Direct-to-Patient Pressure into Program Strategy.
Read on for Bryce's insights.
Read more »
US Pharma Marketing
